Can Fat-Like molecules trick the gut into releasing appetite hormones?
NCT ID NCT07771166
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This trial explores whether two naturally occurring fat-like molecules, arachidonoyl-taurine and oleoyl-taurine, can increase levels of GLP-1 and other gut hormones that help regulate appetite and blood sugar. Healthy adults aged 18 to 45 will receive each compound, a placebo, or both in random order, along with a liquid meal, to see how their hormone levels respond. The study is double-blind and cross-over, meaning neither participants nor researchers know which treatment is given, and each person serves as their own comparison. The goal is to understand whether these molecules could one day be used to support metabolic health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Arachidonoyl-taurine and oleoyl-taurine, two naturally occurring fat-like molecules, taken by mouth
- What this could lead to
- If these molecules boost GLP-1, they could point toward a new way to manage appetite and blood sugar, potentially aiding diabetes or obesity treatments.
- What could go wrong
- This is a small, early-stage trial in healthy people, so results may not apply to those with disease. The compounds may also cause side effects or fail to show a meaningful effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 18 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 45 years * Body mass index between 18.5-27 kg/m2 * Informed consent * Weight stable in the past 3 months Exclusion Criteria: * Regular tobacco smoking or use of other nicotine-containing products * Allergy or intolerance to ingredients included in the test compounds or standardised meals * Glycated haemoglobin (HbA1c) \>48 mmol/mol * Anaemia (haemoglobin below 8.3 mmol/L) * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 times upper normal values (Normal values: ALT \< 70 U/L, AST \<45 U/L) * Nephropathy (eGFR\<90mL/min/1.73 m2) and/or albuminuria (\>30 mg/g albumin in urine)) * Women of childbearing potential who are not using effective contraception * Pregnancy or breastfeeding * History of hepatobiliary or gastrointestinal disorder(s) * Use of weight loss medication within the last 6 months * Any physical or psychological condition, or ongoing medication, that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiometabolic conditions are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.